Your session is about to expire
← Back to Search
Omalizumab for Peanut Allergy (OUtMATCH Trial)
OUtMATCH Trial Summary
This trial is testing whether omalizumab, an allergy medication, can help people with peanut allergies eat foods they're allergic to without having severe symptoms.
OUtMATCH Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowOUtMATCH Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.OUtMATCH Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have conditions or factors that could affect the accuracy or understanding of the study results.You have allergies to at least two out of six specific foods (milk, egg, wheat, cashew, hazelnut, walnut). This is to ensure that participants are likely to maintain their allergies throughout the study and not develop tolerance to these foods.I have severe or poorly controlled asthma.My weight and IgE levels fit the requirements for omalizumab treatment.My skin condition is severe and not well-managed.I am not having sex or am using effective birth control methods.I am in the early phase of my allergy shot treatment.I am a woman who can have children and have a negative pregnancy test.I have not taken steroids for more than two days in the last month, except for asthma.I have or am being checked for cancer.You have had a severe allergic reaction in the past to certain foods that will be used in this study, which caused serious symptoms like difficulty breathing or needing a breathing tube.I was hospitalized or visited the ED for asthma within the last 6 months.You are sensitive or allergic to any of the ingredients in the oral food challenge material, oral immunotherapy, or drugs related to omalizumab.Participating in the study could potentially be risky for you.You have experienced a negative reaction to omalizumab in the past.I experienced severe side effects from the placebo during the screening test.You have taken experimental drugs in the 24 weeks leading up to the screening.I have had a condition related to high eosinophil levels in my GI tract within the last 3 years.I haven't had immunotherapy for food allergies in the last 6 months.I haven't had certain immune therapies like Xolair or Dupixent in the last 6 months.I am using a highly effective form of birth control.My lung function test shows less than 80% of the expected value or my FEV1/FVC ratio is below 75%.I have a severe medical condition not listed that may affect my trial participation.I've had 2 or more steroid treatments for asthma in the last 6 months.I am currently taking steroids, antidepressants, or beta-blockers.I use oral, injected, or implanted hormonal birth control.I had a reaction to ≤100 mg of peanut protein during a blind test.I have a positive allergy test result for specific foods.I use more than 500 mcg daily of inhaled corticosteroids for asthma or COPD.I react to ≤300 mg of certain foods with severe symptoms.I am willing to learn how to use an epinephrine autoinjector.I have been on a breathing machine for asthma before.
- Group 1: Stage 1: Placebo for Omalizumab as Monotherapy
- Group 2: Stage 1: Omalizumab OLE
- Group 3: Stage 2: Omalizumab
- Group 4: Stage 3: DBPCFC Based Treatment
- Group 5: Stage 1:Omalizumab as Monotherapy
- Group 6: Stage 2: Omalizumab + Placebo OIT
- Group 7: Stage 2: Omalizumab-Facilitated OIT
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In how many different medical facilities is this experiment being conducted presently?
"The 11 clinical trial sites for this study are as follows: -Children's Hospital of Philadelphia: Division of Allergy and Immunology in Philadelphia, Pennsylvania-Massachusetts General Hospital, Department of Medicine: Allergy & Clinical Immunology Unit in Boston, Massachusetts-Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology in New york, New York -10 other locations."
What are Multi-Allergen Oral Immunotherapy's most popular applications?
"Multi-Allergen Oral Immunotherapy is a medical intervention used to help those with allergies to airborne substances. Additionally, it can also assist patients who suffer from moderate asthma that is not controlled by other methods, such as inhaled corticosteroids or histamine h1 antagonists."
Does this research project allow people who are over 18 years old to participate?
"According to the study's prerequisites, patients that 1 to 55 years old can apply to participate. Out of the 296 similar clinical trials, this is one of the 94 trials catering to a younger demographic and 202 trials for older patients."
How can I sign up for participation in this research project?
"This study, which is testing a new peanut allergy treatment, is seeking 225 participants who are between 1 year and 55 years old. To be eligible, patients must also be willing to either abstain from heterosexual intercourse or use effective contraception methods."
Are there other medical studies that have used Multi-Allergen Oral Immunotherapy?
"The first study into Multi-Allergen Oral Immunotherapy took place a decade ago at the London Chest Hospital. Since that time, there have been 103 completed studies with 23 more ongoing. The majority of the active studies are located in Philadelphia, Pennsylvania."
Could you detail the risks associated with Multi-Allergen Oral Immunotherapy?
"There is some evidence from earlier clinical trials to support the efficacy of this immunotherapy, as well as data from multiple rounds of safety testing, so it received a score of 3."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Share this study with friends
Copy Link
Messenger